Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
18.58
-0.38 (-2.00%)
At close: Dec 30, 2025, 4:00 PM EST
18.36
-0.22 (-1.18%)
Pre-market: Dec 31, 2025, 9:02 AM EST
Mesoblast Revenue
In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth. Mesoblast had revenue of $7.02M in the half year ending June 30, 2025, with 458.55% growth.
Revenue (ttm)
$17.20M
Revenue Growth
+191.39%
P/S Ratio
135.98
Revenue / Employee
$212,321
Employees
81
Market Cap
2.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | 16.72M | -619.00K | -3.57% |
| Jun 30, 2018 | 17.34M | 14.93M | 618.95% |
| Jun 30, 2017 | 2.41M | -40.14M | -94.33% |
| Jun 30, 2016 | 42.55M | 22.79M | 115.31% |
| Jun 30, 2015 | 19.76M | - | - |
| Jun 30, 2014 | - | - | - |
| Jun 30, 2013 | - | - | - |
| Jun 30, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MESO News
- 1 day ago - Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line - GlobeNewsWire
- 19 days ago - Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD - GlobeNewsWire
- 27 days ago - Mesoblast Participation at Piper Sandler Conference - GlobeNewsWire
- 5 weeks ago - Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue - GlobeNewsWire
- 5 weeks ago - Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids - GlobeNewsWire
- 6 weeks ago - James M. O'Brien Appointed Chief Financial Officer at Mesoblast - GlobeNewsWire
- 2 months ago - Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation - GlobeNewsWire
- 2 months ago - Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch - GlobeNewsWire